Home
About
Overview
Sharing Data
ORCID
Help
History (44)
Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).
Co-Principal Investigator
Intergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
Novel drug targets in acute leukemia.
Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia.
See All 44 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia.
Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. Blood Rev. 2022 05; 53:100908.
View in:
PubMed
subject areas
Acute Disease
Adult
Antineoplastic Agents
Asparaginase
Humans
Incidence
Precursor Cell Lymphoblastic Leukemia-Lymphoma
authors with profiles
Wendy Stock